Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective
immune response to kill tumor cells.
The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients
with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of initial
definitive therapies.